At the 61st ASH Annual Meeting & Exposition, Naval Daver, MD Anderson Cancer Center, discusses his presentation: Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy.
1. What are the current therapeutic options for elderly patients with relapsed or refractory AML ineligible for chemotherapy? (0:05)
2. Could you tell us a little about the mechanism of action of idasanutlin? (1:24)
3. What is the rationale for the combination of venetoclax and idasanutlin? (2:50)
4. Could you tell us a little about the phase 1b study and its efficacy and safety findings? (4:36)
5. What progress has been made in identifying biomarkers of response to this combined therapy? (6:30)
Naval Daver has received consulting fees from Abbvie, Genentech, BMS, PFizer, Forty-Seven, DAiichi Sankyo, Astellas, Celgene and Novartis. He has received research funding from Abbvie, Genentech, BMS, PFizer, Forty-Seven, DAiichi Sankyo, Astellas, Celgene and Novartis.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Leukaemia
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial
Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society […]
Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia
At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia. Questions 1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05) 2. Following discontinuation of TKIs in patients with CML, when are […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!